SURVYR

PACB

Pacific Biosciences of California, Inc.
$2.45
+$0.20 (8.89%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-49%-27%-6%+16%+37%Oct 2025Oct 2026Apr 202652w low $1.07
PACBSPY
Wall St. Highest PT $3.05 (+24.5%) Wall St. Avg PT $2.40 (-2.0%)
$1$2$2$3$3POC $1Hi $3Avg $2
Underwater Drawdown %Max DD -58.4%Current -14.6%
0.0%-58.4%
Relative Strength vs SPY+3.7% vs SPYOutperforming
+70%0%-70%
1W
+$0.49 (25.00%)
1M
+$0.83 (51.23%)
3M
+$1.06 (76.26%)
6M
+$0.87 (55.06%)
YTD
+$0.58 (31.02%)
1Y
+$0.36 (17.22%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
7 analysts · mean score 2.12
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$2.45
Average target$2.40
−$0.05 (−2.0%) downsideaverage target vs current price
CurrentAverageMedian
Low$1.25
Median$2.40
High$3.05
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-05-11 · Barclays reiterated Underweight on PACB
Reiterated
2026-04-14 · Barclays reiterated Underweight on PACB
Downgrade
2026-03-06 · Barclays downgraded PACB from Equal-Weight to Underweight
Reiterated
2025-12-15 · Barclays reiterated Equal-Weight on PACB
Reiterated
2025-11-11 · Piper Sandler reiterated Neutral on PACB
Reiterated
2025-11-10 · Stephens & Co. reiterated Overweight on PACB
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$665.2M
P/E (next 12 months, estimated)-5.1
52-week range$1.07 – $3.44
Revenue growth (latest quarter vs a year ago)-1.9%
Dividend yieldNo dividend
Analyst consensusBuy (7)
Average analyst price target$2.40 (-2%)

What they do

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for PACB yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

PACB earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus-$0.13 range -$0.14–-$0.12
Revenue consensus$39.5M 6 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.14est -$0.13−10.4%Below estimates
May 7, 2026-$0.12est -$0.13+8.7%Above estimates
Feb 12, 2026-$0.12est -$0.13+10.8%Above estimates
Nov 5, 2025-$0.12est -$0.14+15.1%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 18:14:16 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.210.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$39.0M-1.9%
2026-03-31$37.2M–
2025-12-31$44.6M–
2025-09-30$38.4M–
2025-06-30$39.8M–

News & catalysts

More news
Pacific Biosciences of California, Verily Health Agree on Multi-Year Biomedical AI Collaboration
MT Newswires · Oct 19
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
GlobeNewswire · Oct 19
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
StockStory · Oct 16
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Zacks · Oct 14
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
GlobeNewswire · Oct 14
Rating changes
Reiterated
2026-05-11 · Barclays reiterated Underweight on PACB
Reiterated
2026-04-14 · Barclays reiterated Underweight on PACB
Downgrade
2026-03-06 · Barclays downgraded PACB from Equal-Weight to Underweight
Reiterated
2025-12-15 · Barclays reiterated Equal-Weight on PACB
Reiterated
2025-11-11 · Piper Sandler reiterated Neutral on PACB
Reiterated
2025-11-10 · Stephens & Co. reiterated Overweight on PACB

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Gibson James R Ii
See Remarks · 2026-10-06
Sell
$2.1M
Van Oene Mark
See Remarks · 2026-08-17
Sell
$30.4K
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:14:16 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026